SAB Biotherapeutics (SABS) Share-based Compensation (2020 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Share-based Compensation data on file, last reported at $97.4 million in Q1 2026.

• Quarterly Share-based Compensation rose 15790.34% year-over-year to $97.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.4 million (up 4973.78% YoY) and the FY2025 annual result came in at $38.0 million, up 503.17% from the prior year.
• Share-based Compensation advanced to $97.4 million in Q1 2026, from -$2.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $97.4 million in Q1 2026 to a low of -$2.0 million in Q4 2025.
• A 5-year average of $6.0 million and a median of $578203.0 in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2025 — Share-based Compensation tumbled 490.9% — and 2026, when it soared 15790.34%.
• Tracing SABS's Share-based Compensation over 5 years: stood at -$2.0 million in 2022, then surged by 54.64% to -$893030.0 in 2023, then jumped by 61.54% to -$343494.0 in 2024, then plunged by 490.9% to -$2.0 million in 2025, then jumped by 4898.72% to $97.4 million in 2026.
• The last three Share-based Compensation figures came in at $97.4 million (Q1 2026), -$2.0 million (Q4 2025), and $800764.0 (Q3 2025), per Business Quant data.